IMDX vs IR · rev $271.0K vs P/E 49, rev $3.90B
Insight Molecular Diagnostics Inc. (IMDX) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
Latest reported IR revenue for 2026-06-30 was $3.90B. Net income was $448.9M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
IMDX currently screens at market cap $0. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the IMDX and IR stock pages for the full models.
Not investment advice.